An observational study in Hypercholesterolemia, sponsored by JW Pharmaceutical. Completed at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.
Sponsored by JW Pharmaceutical · Observational
A Multi-center, Open-label, Observational Study to Compare and Evaluate the Efficacy and Safety of Livalozet® according to the Presence or Absence of Diabetes Mellitus in Hypercholesterolemia Patients
A Multi-center, Open-label, Observational Study
1,238 studies on the registry are indexed under Hypercholesterolemia; 109 are open to participants now.
This study's enrollment of 1,538 is above the median of 800 across 185 observational studies indexed under Hypercholesterolemia.
Browse Hypercholesterolemia studies →JW Pharmaceutical is the lead sponsor of 75 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants will be selected from adult patients aged 19 years or older diagnosed with hypercholesterolemia who are receiving routine clinical care at participating centers. The population includes both patients with and without diabetes mellitus, reflecting real-world treatment practices. Eligible patients must provide informed consent to participate in this observational study.
Exclusion Criteria:
- Contraindications to Livalozet®
Observational study; LDL-C and lipid parameters will be followed; no intervention assigned.
Observational study; LDL-C and lipid parameters will be followed; no intervention assigned.
Percent change from baseline in LDL-C level at Week 24
Time frame: From enrollment to the end of treatment at 24 weeks
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
JW Pharmaceutical